Compare Diamondback Energy Inc (FANG) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Diamondback Energy Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? Diamondback Energy Inc trades at $190.58 (market cap $53.38B), while Vertex Pharmaceuticals Incorporated trades at $480.91 (market cap $121.09B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 2.3× Diamondback Energy Inc's market cap, and Diamondback Energy Inc pays a 2.32% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals.
| FANG | VRTX | |
|---|---|---|
Market Cap | $53.38B | $121.09B |
Sector | Energy | Health |
52-Week High | $213.69 | $529.59 |
52-Week Low | $134.53 | $366.54 |
Enterprise Value | $67.11B | $115.83B |
Dividend Yield | 2.32% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Diamondback Energy (FANG) trades at $190.69, showing slight daily weakness but maintaining a bullish technical outlook with strong analyst support. The company demonstrates solid revenue growth reaching $14.93B in 2025, though net margins have compressed to 1.88%. Recent earnings show mixed results with Q1 2026 beating expectations while Q4 2025 missed, with Q2 2026 results pending. The stock benefits from overwhelming analyst consensus with 90% buy ratings and a $234.50 price target representing 23% upside potential.
FANG presents a compelling growth story with expanding operations and strong cash generation, though investors face margin compression risks amid volatile energy markets. The stock's elevated P/E ratio of 193.63 reflects growth expectations, while technical indicators suggest near-term support around $189. Institutional sentiment remains positive with upcoming Q2 earnings on August 3, 2026, serving as the next key catalyst.
Vertex Pharmaceuticals (VRTX) trades at $476.31, down 0.82% over 24 hours, with a bullish technical signal despite mixed moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $4.47, and maintains robust profitability with a net income margin of 35.51%. Recent news highlights a $10 billion acquisition of Crinetics Pharmaceuticals, aimed at expanding its endocrinology portfolio with potential peak sales of over $5 billion.
The outlook remains positive with analyst consensus favoring a buy rating (83.92%) and a price target of $538, suggesting 13% upside. Key risks include integration challenges from the Crinetics deal and reliance on cystic fibrosis treatments, while strong cash flow and earnings growth support long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Diamondback Energy Inc
Diamondback Energy is an independent oil and gas producer in the United States. The company operates exclusively in the Permian Basin. At the end of 2021, the company reported net proven reserves of 1.8 billion barrels of oil equivalent. Net production averaged about 375,000 barrels per day in 2021, at a ratio of 60% oil, 20% natural gas liquids, and 20% natural gas.
Read more on FANG →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
